Publications

Howaldt, S.; “Real-world data with mesalazine 1600 mg tablet (AsacolĀ® 1600) in patients with ulcerative colitis in a German tertiary CED center”; Z Gastroenterol 2022; 60(08): e424-e425.

Howaldt S, Becker CK, Becker JA, Poinas A; “Cost savings associated with ferric maltol and the reduced use of intravenous iron based on real world data”, , P1102, Abstract UEGW 2021:

Steiner IM, Howaldt S, Stargardt T.; “Cost-utility analysis of biologic therapy vs. early surgery in ulcerative colitis”; Abstract EuHEA student-supervisor conference 2021 Rotterdam/ online.

Howaldt S, Becker CK, Becker JA, Poinas A-C.: “Cost savings associated with ferric maltol and the reduced use of intravenous iron based on real world data,” Abstract ECCO 2021: P592; J. Crohn’s Colitis. 2021;15:S541-S542.

Howaldt S, Becker CK; Becker JA; Poinas A-C.: WB12 “Reducing the need for intravenous iron in patients with iron deficiency (with or without anemia): Real-world data before and after introduction of oral iron(III) maltol.” The Internist 2021 (Suppl 2): p-155.

Howaldt S et al Gastroenterology 2018; 154 (Suppl 1): S-998: “CEDUR: Implementation of a Long-Term Observation Registry in German IBD Patients”; Abstract DDW 2018.

Research grant (BSFZ) from the Federal Ministry of Education and Research for eligible projects